{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015232","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.850807+00:00","generated_at":"2026-06-24T02:43:38.673022+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kodiak Sciences: BEACON Phase 3 tarcocimab meets primary endpoint in retinal vein occlusion","bullets":["BEACON Phase 3 randomized 568 RVO patients to tarcocimab 5 mg q8w after 2 monthly loads vs aflibercept 2 mg q4w.","Primary endpoint of non-inferior BCVA change at week 24 met in BRVO (p=0.0004) and overall RVO (p=0.0243).","Tarcocimab dosed 4 times vs aflibercept 6 times in first 24 weeks, showing extended durability.","Safety favorable: low intraocular inflammation (1.4% vs 0.4%); no vasculitis or retinal artery occlusion.","Full primary results to be presented at ophthalmology congresses in September 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015232","json":"https://secwatch.observer/filing/0000950170-22-015232.json","markdown":"https://secwatch.observer/filing/0000950170-22-015232.md","text":"https://secwatch.observer/filing/0000950170-22-015232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022015232/0000950170-22-015232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022015232/kod-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:43:38.673022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}